Hims & Hers Health (HIMS) shares surged Monday after the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) said compounding pharmacies could continue to produce copycat weight-loss drugs while it reconsiders whether there is a shortage of their active ingredient.

The FDA is facing a lawsuit after it ruled earlier this month that Eli Lilly’s (LLY) popular weight-loss treatments Mounjaro and Zepbound were 澳洲幸运5官方开奖结果体彩网:no longer on its shortages list. The agency allows companies like Hims & Hers to produce compounded copycat drugs when the originals are hard to obtain, all𝓰owing them to benefit from the demand for obesity treatments.&n꧟bsp;

In a court filing Friday, the FDA said it would not take action against companies that are in violation of its decision last week while it reconsiders the matter. The suit was fi🉐led by the Outsourcing Facilities Association, a trade association representing compounding pharmacies.

Shares of Hims & Hers gained nearly 10% to c꧙lose at $20.50 Monday. The stock has more than doubled💫 in value since the start of the year.